In Shanghai, on February 24, 2021 – WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completed US$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International Holdings Limited ("ABC International"), Sunland Capital and CCBI Tech Venture, alongside existing shareholder YF Capital, with CEC Capital Group serving as the exclusive financial adviser. WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.
Guangzhou Weiyuan (Vision Medicals) Gene Technology Co., Ltd. (hereinafter referred to as “Vision Medicals” or the “Company”), a leader in the infection precision medicine industry, recently announced the completion of a Series B financing round of several hundred million RMB. This round of financing was led by CDH Investment, with participation from CICC Qichen and existing shareholders, Volcanics Venture and Cash Capital. This round of financing will primarily be used for funding product R&D, establishing a clinical testing network, driving product registration efforts, constructing manufacturing facilities, improving clinical services, and increasing brand marketing. CEC Capital Group served as the exclusive financial advisor of Vision Medicals in this transaction.
4Paradigm recently announced the completion of its USD 700 million Series D financing round. This round was led by Boyu Capital, Primavera Capital, and Hopu Investments, with followers including CDB Capital, China Reform Holdings, JIC TECH-INV, CSC Financ
CEC Capital Group serves as exclusive financial advisor On January 7, 2021, SF Holdings (hereinafter referred to as the "Company") announced that it has raised funding through Hive Box Holdings Ltd (hereinafter referred to as "Hive Box Cayman"), a joint
CEC Capital Group serves as exclusive financial advisor Beijing Haosi (Health) Biotechnology Co., Ltd. (hereinafter referred to as "Haosi Bio" or the "Company"), a leading provider of solutions for clinical mass spectrometry detection, today announced th